n a retrospective study including 9035 prediabetic patients, the occurrence of NODM and cardiovascular disease and death was 23.5% and 16.7%, respectively, in statin-naïve subjects and 28.5% and 12.0%, respectively, in statin users during a follow up of 2.5–4.1 years [Wang et al. 2014]. Of note, both the increase in NODM and the reduction in cardiovascular disease and death were dose- and time- dependent of the statin treatment [Wang et al. 2014].